证券代码：300275 证券简称：梅安森 公告编号：2025-057 重庆梅安森科技股份有限公司 关于公司 2022 年限制性股票激励计划第三个归属期归属结果 暨股份上市公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次归属的限制性股票归属日（即上市流通日）：2025 年 6 月 18 日。 2、本次符合归属条件的 2022 年限制性股票激励计划第三个归属期归属激励 对象共计 89 人，归属的限制性股票数量为 251.136 万股，占目前公司总股本的 0.8230%。 3、公司董事及高级管理人员本次归属的股票按相关法律法规的要求执行， 其余激励对象归属的股票无限售安排。 根据重庆梅安森科技股份有限公司（以下简称"公司"或"梅安森"）2021 年度股东大会的授权，公司于 2025 年 6 月 3 日召开第六届董事会第五次会议审 议通过了《关于公司 2022 年限制性股票激励计划第三个归属期归属条件成就的 议案》。近日，公司办理完成了 2022 年限制性股票激励计划第三个归属期归属 股份的登记工作，现将有关事项说明如下： 一、2022 ...

Core Points - Meiansen submitted an application to the Shenzhen Stock Exchange on February 14, aiming to raise up to 180 million yuan through a private placement, with the net proceeds intended to enhance working capital and improve financial structure [2] - Meiansen is a high-tech enterprise in the field of safety, possessing a complete technology and product chain, focusing on smart mining safety monitoring and control, utilizing technologies such as IoT, AI, and cloud computing [2] - On June 12, Meiansen announced the termination of its application for the private placement, following a board decision on June 9 to withdraw the application due to various considerations including market conditions and company strategy [2][3] Company Overview - Meiansen has capabilities in ITSS operation services and is engaged in the development of smart mining safety solutions [2] - The company leverages advanced technologies like 2D/3D GIS, virtual reality, and UWB to expand its applications in multiple sectors [2] Recent Developments - The decision to withdraw the application was made after thorough communication and analysis among relevant parties, considering the current market environment and the company's strategic direction [3]

关于收到深圳证券交易所《关于终止对重庆梅安森科技股份有限公司 申请向特定对象发行股票审核的决定》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）于 2025 年 6 月 9 日 召开第六届董事会第六次会议和第六届监事会第五次会议，会议审议通过了《关于公司 终止向特定对象发行股票事项并撤回申请文件的议案》，同意公司终止本次向特定对象 发行股票事项并撤回申请文件。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn） 披露的《关于公司终止向特定对象发行股票事项并撤回申请文件的公告》。 2025 年 6 月 10 日，公司和保荐机构东方证券股份有限公司向深圳证券交易所（以 下简称"深交所"）提交了《重庆梅安森科技股份有限公司关于撤回 2024 年度向特定 对象发行股票申请文件的申请》和《东方证券股份有限公司关于撤回重庆梅安森科技股 份有限公司 2024 年度向特定对象发行股票申请文件的申请》，申请撤回向特定对象发 行股票申请文件。 证券代码：300275 证券简称：梅安森 公告编号：202 ...

Core Viewpoint - The company Meiansen has decided to terminate its plan to issue shares to specific investors and has withdrawn its application, citing market conditions and strategic considerations as the main reasons for this decision [1]. Group 1: Termination of Share Issuance - Meiansen held meetings on June 9, 2025, where the board and supervisory committee approved the termination of the share issuance plan and the withdrawal of the application [1]. - The company emphasized that the decision was made after thorough communication and analysis among relevant parties, considering the current market environment and the company's development strategy [1]. - The termination of the share issuance will not have a significant adverse impact on the company's normal operations and will not harm the interests of the company or its shareholders, especially minority shareholders [1]. Group 2: Previous Share Issuance Plan - The previously disclosed plan aimed to raise a total of up to 180 million yuan, with the net proceeds intended to supplement working capital [2]. - The shares were to be fully subscribed by the company's actual controller, Ma Yan, at a price of 7.74 yuan per share, which would increase his shareholding from 15.38% to 21.37% if the maximum number of shares were issued [2]. - Ma Yan is the controlling shareholder and chairman of the company, and his participation in the share issuance constitutes a related party transaction [2]. Group 3: Underwriting Information - The lead underwriter for the share issuance was Dongfang Securities Co., Ltd., with representatives Guo Jiange and Yuan Hui overseeing the process [3].

Group 1 - Meiansen announced the termination of its planned private placement to its controlling shareholder after nearly a year of planning, citing market conditions and company strategy as reasons for the decision [2] - The private placement was initially proposed on July 24, 2024, and approved by the shareholders on August 13, 2024, with the application submitted to the Shenzhen Stock Exchange on January 9, 2025 [2] - The controlling shareholder, Ma Yan, held only 15.42% of the shares before the planned issuance, and nearly half of his shares were pledged for financing as of the end of 2024 [2][3] Group 2 - The Shenzhen Stock Exchange requested details on Ma Yan's funding sources for the subscription, considering his financial status and the risks associated with high share pledges [3] - Ma Yan planned to finance the subscription primarily through further pledging of his shares, with intentions to raise up to 120 million yuan [3] - The proposed subscription price was 7.74 yuan per share, while the market price on the day of the inquiry response was 16.11 yuan, indicating a significant potential profit if the plan had proceeded [3] Group 3 - As of June 9, 2025, Meiansen's market capitalization was 3.894 billion yuan [5] - The company, established in May 2003 and listed on the Shenzhen Stock Exchange in November 2011, focuses on monitoring and warning technology and equipment in the safety sector [2] - In 2024, over 95% of Meiansen's revenue came from mining monitoring products, highlighting its strong market position in this niche [4]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：300275 证券简称：梅安森 公告编号：2025-055 重庆梅安森科技股份有限公司 关于公司终止向特定对象发行股票事项并撤回申请文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）于 2025 年 6 月 9 日召开第六届董事会第六次会议和第六届监事会第五次会议，会议审议通过 了《关于公司终止向特定对象发行股票事项并撤回申请文件的议案》，同意公司 终止本次向特定对象发行股票事项并撤回申请文件。现将相关事项公告如下： 一、本次向特定对象发行股票事项的基本情况 2024 年 7 月 24 日，公司召开第五届董事会第二十八次会议和第五届监事会 第二十二次会议审议通过了《关于公司 2024 年度向特定对象发行股票方案的议 案》及相关事项。2024 年 8 月 13 日，公司召开 2024 年第二次临时股东大会审 议通过了本次向特定对象发行股票方案，并授权董事会全权办理本次向特定对象 发行股票相关事项。 义务。综合考虑当前市场环境、公司发展战略及经营规划等因素，经相关各方充 分沟通、审慎分析 ...

证券代码：300275 证券简称：梅安森 公告编号：2025-054 重庆梅安森科技股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）第六届监 事会第五次会议通知于 2025 年 6 月 4 日以电子邮件方式发出，会议于 2025 年 6 月 9 日在公司会议室以现场方式召开。本次会议应出席监事三人，实际出席监事 三人。本次会议由公司监事会主席主持，董事会秘书列席了会议。本次会议的召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定， 所做决议合法有效。 一、本次监事会会议审议情况 经与会监事认真审议，会议在保证所有监事充分发表意见的前提下，以投票 表决的方式审议通过了以下议案： 1、审议通过《关于公司终止向特定对象发行股票事项并撤回申请文件的议案》 经审核，监事会认为：公司终止向特定对象发行股票事项的审议程序符合《公 司法》《证券法》等有关法律、法规以及《公司章程》的规定。该事项不会对公司 的正常业务经营产生不利影响，不存在损害公司及全 ...

证券代码：300275 证券简称：梅安森 公告编号：2025-053 重庆梅安森科技股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）第六届董 事会第六次会议通知于 2025 年 6 月 4 日以电子邮件方式发出，会议于 2025 年 6 月 9 日在公司会议室以现场与通讯表决相结合的方式召开。本次会议应出席董事 七人，实际出席董事七人（独立董事杨安富以通讯表决方式参加）。本次会议由 公司董事长主持，董事会秘书列席了会议。本次会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的有关规定，所做决议合法有效。 一、本次董事会会议审议情况 经与会董事认真审议，会议在保证所有董事充分发表意见的前提下，以投票 表决的方式审议通过了以下议案： 1、审议通过《关于公司终止向特定对象发行股票事项并撤回申请文件的议 案》 综合考虑当前市场环境、公司发展战略及经营规划等因素，经相关各方充分 沟通、审慎分析后，公司决定终止本次向特定对象发行股票事项并撤回相关申请 ...

证券代码：300275 证券简称：梅安森 公告编号：2025-052 重庆梅安森科技股份有限公司 归属条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次符合归属条件的激励对象共计 89 人，归属的限制性股票数量为 251.136 万股，占目前公司股本总数的比例为 0.8230%。 2、归属股票来源：公司向激励对象定向发行 A 股普通股。 根据重庆梅安森科技股份有限公司（以下简称"公司"或"梅安森"）2021 年度股东大会的授权，公司于 2025 年 6 月 3 日召开第六届董事会第五次会议审 议通过了《关于公司 2022 年限制性股票激励计划第三个归属期归属条件成就的 议案》，现将有关事项说明如下： 一、2022 年限制性股票激励计划简述及已履行的审批程序 （一）公司 2022 年限制性股票激励计划简述 1、激励计划工具：第二类限制性股票 关于公司 2022 年限制性股票激励计划第三个归属期 3、2022 年 5 月 10 日，公司召开 2021 年度股东大会，审议通过了《<重庆 梅安森科技股份有限公司 2022 年限制性 ...